IMMUNOGEN, INC. : Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its ... 4-traders Today NHL is frequently treated with the anticancer antibody, rituximab (Rituxan®), and/or with chemotherapy. The novel agent IMGN529, a TAP compound, contains a B-cell-targeting antibody that has demonstrated marked anticancer activity in preclinical ... |
